Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7408-7412

  Murillo, Horacio ^a   Schmidt, Lucy J ^a   Tindall, Donald J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ANDROGEN; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANDROGENS; APOPTOSIS; BENZOTHIAZOLES; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, HORMONE-DEPENDENT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0035886863     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Regulation of prostatic growth and function by peptide growth factors
2. Growth factor involvement in progression of prostate cancer
3. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-α in the progression of prostatic neoplasms
4. Dimerization of cell surface receptors in signal transduction
5. Cell signaling by receptor tyrosine kinases
6. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
7. Tyrosine kinase inhibition: An approach to drug development
8. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
9. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6, 7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor
10. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
11. Signal transduction through MAP kinase cascades
12. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase
13. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
14. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
15. Current and planned clinical trials with trastuzamab
16. neu expressing non-small cell lung cancer cells
17. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2
18. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer
19. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
20. Requirement of ErbB2 for signaling by interleukin-6 in prostate carcinoma cells
21. Mitogen-activated protein kinase phosphatase I is overexpressed in prostate cancers and is inversely related to apoptosis
22. Activation of mitogen-activated protein kinase associated with prostate cancer progression